Edwards Lifesciences (NYSE: EW ) is a high-quality company with a solid history of growth and high returns. It is a dominant player in the high-tech medical device segment, offering solutions for treatments to structural heart patients. Share prices have underperformed the S&P 500We use Cash Flow Returns On Investment based DCF valuation tools provided by our affiliate company, ROCGA Research.With over 20 years of experience in investment analysis, we are actively seeking out undervalued and quality compani ...

At the EuroPCR 2025, Edwards Lifesciences (EW) has announced new economic and clinical evidence on severe aortic stenosis (AS). The results of a new real-world study, comprising more than 24,000 patients, demonstrated that intervening on the disease before symptoms develop reduces the economic and resource burden on the healthcare system and improves patient outcomes.Presented as a late-breaking clinical trial, the data further contributes to the extensive body of research on this disease. The development i ...

Edwards Lifesciences (EW) 2025 Conference May 13, 2025 01:40 PM ET Speaker0 Travis Steed, the medical device analyst, and continuing our medical device conversations today. Next up, we have Edwards Lifesciences, Bernard Zevigian, if I said that right, CEO, and we got Scott Ullum, CFO. So great, thanks for coming. Good morning. Looking forward to the discussion. Speaker1 Pleasure to be here. Speaker0 Thank you. And so I I wanna open up with kind of a big picture question. And you've laid out commitments at t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (949) 250-2500 (Registrant's telephone number, including area code) For the transition period from to Commission file number 1-15525 EDWARDS LIFESCIENCES CORPORATION (Exact name of registra ...

Edwards Lifesciences‘ EW shares are trading higher Thursday after the company reported first-quarter 2025 sales of $1.41 billion.That’s almost in line with the consensus of $1.40 billion and the management guidance of $1.35 billion—$1.43 billion, up 6.2% year-over-year or 7.9% on an adjusted basis.Also Read: Trump Tariffs Spare Drugmakers But Threaten Diabetes Device IndustryIn the first quarter, the company reported: An adjusted EPS of 64 cents. It beat the consensus of 60 cents and remained within the man ...

Edwards Lifesciences Corporation (EW) reported first-quarter 2025 adjusted earnings per share (EPS) of 64 cents, which surpassed the Zacks Consensus Estimate by 6.7%. The figure increased 16.4% from the year-ago quarter’s level. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar).The quarter’s one-time adjustments primarily include certain litigation expenses and amortization of intangible assets.GAAP EPS from continuing operations was 62 cents compared with 54 cents in the first quarte ...

Financial Data and Key Metrics Changes - Total company sales grew 8% to $1.041 billion in Q1 2025, driven by a broad portfolio of therapies for structural heart disease [9][10] - Adjusted EPS for the quarter was $0.64, with GAAP EPS at $0.62 [38] - Adjusted gross profit margin was 78.7%, slightly up from 78.5% in the previous year [39] - Full-year total company sales growth guidance is maintained at 8% to 10%, with total sales expected to be between $5.7 billion and $6.1 billion [16][37] Business Line Data and Key Metrics Changes - TAVR sales reached $1.05 billion, a 5.4% increase year-over-year, with growth comparable in both the US and OUS [18][25] - TMTT sales were $150 million, representing a 60% growth, driven by increased adoption of Pascal and Evoque [26] - Surgical product group sales were $251 million, a 3% increase from the prior year [33] Market Data and Key Metrics Changes - TAVR growth was supported by the expansion of SAPIEN 3 Ultra Resilia in Europe, while Japan faced weaker procedure growth and competitive pressure [24][25][111] - The NCD for Evoque is expected to enhance patient access and treatment opportunities [57] Company Strategy and Development Direction - The company is focused on TAVR innovation and expanding access to treatment options for all AS patients, with upcoming indication approvals expected to drive growth [11][16] - The strategy includes a commitment to developing a transcatheter tricuspid valve and advancing surgical innovations [12][13] - The company aims to address the significant undertreatment of AS in Japan and enhance capabilities in the region [112] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to offset tariff impacts and the dilution from the Yenovale acquisition [16][37] - The company anticipates a multiyear growth opportunity from TAVR and TMTT innovations, with a strong focus on patient care and physician support [11][16][100] Other Important Information - The company has approximately $3 billion in cash and cash equivalents, with ongoing share repurchase programs [43] - The company is committed to maintaining a strong balance sheet while investing in strategic growth areas [43] Q&A Session Summary Question: EPS guidance maintenance despite tariffs and acquisition impacts - Management clarified that the EPS guidance accounts for tariff impacts of about $0.05 and Yenovale acquisition impacts of $0.05 to $0.10 [51][53] Question: Impact of NCD on Evoque ramp-up - Management indicated that the NCD ensures access for Medicare beneficiaries and aligns with expectations for 2025 growth [57] Question: TAVR business trends and referral patterns - Management noted that physicians are taking time to understand new data, with plans to support market development post-indication approval expected in Q2 [67][68] Question: Capacity constraints and NCD implications - Management discussed the need for NCD updates to cover asymptomatic patients and expand treatment centers [83][84] Question: Trends in Japan's market - Management acknowledged weaker growth in Japan but remains optimistic about long-term opportunities due to an aging population [111][113]

Edwards Lifesciences Corporation One Edwards Way · Irvine, CA USA · 92614 Phone: 949.250.2500 · www.edwards.com FOR IMMEDIATE RELEASE Media Contact: Amy Meshulam, 949-250-4009 Investor Contact: Mark Wilterding, 949-250-6826 EDWARDS LIFESCIENCES REPORTS FIRST QUARTER RESULTS IRVINE, CA, Apr. 23, 2025 — Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended Mar. 31, 2025. Recent Highlights 2025 Outlook "The many milestones achieved this quarter are the result of our structural ...

Wall Street analysts expect Edwards Lifesciences (EW) to post quarterly earnings of $0.60 per share in its upcoming report, which indicates a year-over-year decline of 9.1%. Revenues are expected to be $1.4 billion, down 12.2% from the year-ago quarter.The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.Ahead of a company's earnings disclosure, it is cruci ...

Edwards Lifesciences Corp. (EW) is scheduled to report first-quarter 2025 results on April 23, after market close.In the last reported quarter, the company’s adjusted earnings per share of 59 cents beat the Zacks Consensus Estimate by 7.27%. Its earnings beat estimates in two of the trailing four quarters and matched on the other two occasions, the average surprise being 2.60%. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)Q1 EstimatesThe Zacks Consensus Estimate for the company’s ...